PAI-1 expression may be modulated by FXR. (A-C) MPHs were treated with different concentrations of CDCA for 6 hours: (A) the amount of PAI-1 in the supernatant of the culture medium and (B-C) the protein expression levels of PAI-1 in the MPHs (N = 4). (D-G) MPHs were treated with different concentrations of TCA for 6 hours: (D-E) the protein and (F) relative Serpine1 mRNA levels of PAI-1 in MPHs (N = 4); (G) the amount of PAI-1 in the supernatant of the culture medium (N = 4). (H-K) MPHs were treated with different concentrations of DY268 for 6 hours: (H) the relative Serpine1 mRNA and (I) PAI-1 protein levels in the supernatant of the culture medium; (J-K) the PAI-1 protein level in the MPHs (N = 4). (L-M) C57BL/6J mice treated with 50 mg/kg per day CDCA for 4 days: (L) liver Serpine1 mRNA (N = 5); (M) plasma PAI-1 levels (N = 5). (N-O) C57BL/6J mice treated with 200 mg/kg per day TCA for 4 days: (N) liver C57BL/6J mRNA (N = 5); (O) plasma PAI-1 levels (N = 5). The data are represented as the mean ± SEM, n.s. P > .05; ∗P < .05; ∗∗P < .01; ∗∗∗P < .001 vs the lowest concentration of FXR ligands or Veh group. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; n.s., no significance; Veh, vehicle.